Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
Date:3/11/2009

current liabilities 4,877 3,682 Long-term liabilities: Convertible debt 553 2,764 Debt discount (66) (651) Net long-term convertible debt 487 2,113 Asset retirement obligation 2,217 2,217 Total liabilities 7,581 8,012 Stockholders' equity (deficit): Common stock; $.01 par value; authorized shares 500,000,000; issued and outstanding shares, 122,494,010 in 2008 and 121,904,312 in 2007 1,225 1,219 Additional paid-in capital 342,378 341,270 Accumulated deficit (346,426) (330,759) Accumulated other comprehensive loss: Unrealized loss on investment - (242) Net stockholders' equity (deficit) (2,823) 11,488 Total liabilities and stockholders' equity (deficit) $4,758 $19,500

                              INSMED INCORPORATED
                   Consolidated Statements of Operations
              (in thousands, except per share data - unaudited)

                               Three Months Ended         Twelve Months Ended
                                   December 31,               December 31,
                               2008          2007         2008          2007

    Sales, net                   $-            $-           $-          $423
    Royalties                    61            41          144           121
    License income                -            62            -         1,607
    Grant revenue                 -             -        1,044             -
    Other expanded access
     Program income, net      2,878         2,032       10,511         5,430
      Total revenues  
'/>"/>
SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  AmnioChor Inc., an early stage biotech ... pleased to announce that the Musculoskeletal Transplant Foundation of ... invest in their seed round of development of the ... capabilities. AmnioChor,s technology allows cryopreservation of ... stem cells living within those tissues. Amnion is a ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE MKT: ... results will be released on Thursday, August 13, 2015, ... Time, Pfenex management will host a conference call to ... A press release outlining the financial results and business ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) ...
(Date:7/29/2015)... Madison, NJ (PRWEB) , ... July 29, 2015 , ... ... and approval of combination products , in particular, drug/device combinations. The current system ... innovation by the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson ...
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... selected an optimized Erk inhibitor molecule for development, ... of a new class of potential cancer therapies. ... prime target for therapeutic intervention in cancer. Recently ... benefits for B-Raf and Mek inhibitors. Erk inhibitors ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... YORK, Jan. 15 - The Michael J. Fox,Foundation ... total funding for seven research studies aiming to ... drug makers, to,therapeutically target two genes -- LRRK2 ... only partially understood, role in Parkinson,s disease., ...
... Kan., Jan. 15 The Kansas Bioscience,Authority ... bring together,researchers nationwide to create products that ... diseases to disrupt the national economy or,to ... new Collaborative Biosecurity Research Initiative,(CBRI) are to ...
... Group plc (AIM:,PRG), the international pharmaceutical services ... Senior Director, Clinical Trial Management,specializing in oncology-related ... a leading role in the operations, strategic ... portfolio of oncology,business., Over the past ...
Cached Biology Technology:The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinson's Disease 2Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally 2Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally 3Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management 2
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... , July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... the growing mobile commerce market announces a revised version of one ... The commercial will air on CNBC in New York ... and San Francisco metro areas. ... focuses on Wocket,s ability to replace all the cards in your ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... FL. Research to be presented at the upcoming ... Ingestive Behavior (SSIB), the foremost society for research into ... people can become dependent on highly palatable foods and ... the behaviors we observe in drug addicts and those ...
... can make a significant contribution to carbon storage and, ecologists ... and gardeners planted and maintained more trees. The study, published ... Applied Ecology , is the first to quantify how much ... Europe. Using satellite data and information gathered by visiting ...
... Toronto, ON - When it comes to how they ... from humans. Recent studies showed that even genetically ... a disease. This is because each twin has distinct personal ... the same is likely true for forest trees as well, ...
Cached Biology News:Evidence for 'food addiction' in humans 2Plants in cities are an underestimated carbon store 2New research shows forest trees remember their roots 2
... bromide), 50mg/vial. MTT is a pale yellow ... to yield a dark blue formazan product. ... freshly dead cells do not cleave significant ... component of Chemicons MTT assay kit, Catalog ...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
Determin interaction of your protein with Echelons lipids...
Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...
Biology Products: